Internal Medicine, Medical Oncology · Hackensack, NJ
NPI
1578528089
Since 2006
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
2
Medicare group memberships
Hospitals
2
Hospital affiliations
92 2nd St
Hackensack, NJ, 07601
Phone (551) 996-3033
Groups this clinician bills Medicare through
Medicare paid, 2024
$286K
23,732 services
Medicare patients, 2024
481
Average age 76
Drug cost, 2024
$6.5M
1,271 prescriptions
Company payments, 2025
$23K
From 10 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Tatyana A Feldman was code 99214 (office e&m - established), 1,137 times for 426 patients. In total Tatyana A Feldman billed 23,732 services in 27 codes, and Medicare paid $286K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-01-26.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 1,137 | 426 | $103.75 | $118K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 980 | 406 | $13.83 | $14K |
| 99233 Hospital E&M - Subsequent | Facility | 366 | 50 | $100.14 | $37K |
| Q5111 Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg | Office | 348 | 17 | $111.45 | $39K |
| Q5108 Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg | Office | 228 | 12 | $109.28 | $25K |
| 96372 Injection Administration | Office | 119 | 35 | $12.41 | $1,477 |
| 99215 Office E&M - Established | Office | 76 | 60 | $153.58 | $12K |
| 99223 Hospital E&M - Initial | Facility | 70 | 54 | $146.19 | $10K |
| 99238 Hospital Discharge Management | Facility | 50 | 39 | $68.95 | $3,448 |
| 99232 Hospital E&M - Subsequent | Facility | 38 | 21 | $66.42 | $2,524 |
| 99205 Office E&M - New | Office | 34 | 34 | $185.37 | $6,303 |
| 99213 Office E&M - Established | Office | 23 | 16 | $79.31 | $1,824 |
By year: 2022 $264K for 49,977 services; 2023 $246K for 17,409 services; 2024 $286K for 23,732 services.
Lab tests billed to Medicare, 2022
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 780 | 353 | $7.57 | $5,901 |
| 85027 Blood Count | 255 | 170 | $6.28 | $1,603 |
Medicare prescription drug claims, 2024
In 2024, the drug Tatyana A Feldman prescribed most often to Medicare patients was Brukinsa (Zanubrutinib), with 173 prescriptions and refills. In total Tatyana A Feldman wrote 1,271 Medicare prescriptions that cost $6.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Brukinsa Zanubrutinib | 173 | 173 | 23 | $2.6M |
| Calquence Acalabrutinib Maleate | 114 | 114 | 12 | $1.7M |
| Acyclovir Generic | 87 | 113 | 29 | $1,267 |
| Prednisone Generic | 83 | 83 | 27 | $182 |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 83 | 114 | 22 | $513 |
| Fluconazole Generic | 66 | 77 | 25 | $1,879 |
| Valacyclovir Valacyclovir Hcl | 61 | 99 | 19 | $2,616 |
| Venclexta Venetoclax | 56 | 56 | Under 11 | $815K |
| Ciprofloxacin Hcl Generic | 52 | 52 | 17 | $455 |
| Allopurinol Generic | 31 | 41 | 17 | $133 |
| Nyvepria Pegfilgrastim-Apgf | 29 | 29 | Under 11 | $109K |
| Ondansetron Hcl Generic | 29 | 29 | 21 | $267 |
| Prochlorperazine Maleate Generic | 22 | 22 | 15 | $214 |
| Zarxio Filgrastim-Sndz | 21 | 21 | Under 11 | $79K |
| Dexamethasone Generic | 21 | 21 | 16 | $230 |
Brand drugs: - claims; generic drugs: 785 claims; opioid claims: 11.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Tatyana A Feldman $23K ($20K in general payments such as food, travel and fees and $3,200 for research) from 10 companies. The largest payer was Genmab U.S., Inc. with $7,111.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.